Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

Type 2 Diabetes: Assessing the Relative Risks and Benefits of Glucose-lowering Medications

(2010) Richard M. Bergenstal et al.   AMERICAN JOURNAL OF MEDICINE

One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice

(2010) M. Buysschaert et al.   DIABETES & METABOLISM

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

(2010) C. J. Girman et al.   DIABETES OBESITY & METABOLISM

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks

(2010) Takashi Kadowaki et al.   Journal of Diabetes Investigation

Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus

(2010) et al.   Journal of Diabetes Investigation

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Diabetes in Japan: a review of disease burden and approaches to treatment

(2009) Susan E. Neville et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION